Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > U.S. funding 1.6B$ for Novavax's COVID-19

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Apr 19, 2022 5:56pm

138 Views

Post# 34614700

RE:RE:RE:U.S. funding 1.6B$ for Novavax's COVID-19

Also, just a quick question from the previous post - the website says:

"To date, 24 patients have been enrolled and treated in Study II."

Based on our last update is the website out of date?

Also it says

"the Company has been advised by the FDA, to provide clinical assessment data for the primary, secondary and tertiary objective for approximately 20-25 patients treated at the therapeutic dose level."

Presumably we have exceeded the "approximately" criteria? so -- as many have suggested the BTD designation could be imminent?

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing